Peel Hunt reissued their hold rating on shares of Vectura Group (LON:VEC) in a research note issued to investors on Friday, ThisIsMoney.Co.Uk reports.
Several other brokerages have also issued reports on VEC. Shore Capital reissued a hold rating on shares of Vectura Group in a research note on Wednesday, May 8th. Numis Securities reissued a buy rating and issued a GBX 160 ($2.09) price target on shares of Vectura Group in a research note on Wednesday, May 8th. Finally, JPMorgan Chase & Co. dropped their price target on Vectura Group from GBX 110 ($1.44) to GBX 100 ($1.31) and set an overweight rating on the stock in a research note on Wednesday, April 3rd. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company has a consensus rating of Buy and an average price target of GBX 122.86 ($1.61).
Shares of VEC stock opened at GBX 80.05 ($1.05) on Friday. Vectura Group has a one year low of GBX 65.85 ($0.86) and a one year high of GBX 90.15 ($1.18). The company has a market capitalization of $531.43 million and a P/E ratio of -6.06. The company has a current ratio of 2.35, a quick ratio of 1.90 and a debt-to-equity ratio of 0.81.
Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta and Anoro Ellipta for the treatment of COPD.
Read More: What is systematic risk?
Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.